Until law, GLP-1 drugs were used to treat diabetes, obesity and even the recent evidences suggest that it could as well be used to treat chronic kidney problems. There is yet another research, published in JAMA Psychiatry on February 25, titled Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial that explores if GLP-1 receptor agonist semaglutide reduce alcohol consumption and cravings in adults with alcohol use disorder.

What Do Studies Say?

The research was conducted over a period of 9 weeks, where in the randomized clinical trial, the participants who were administered semaglutide, it led to reductions in some but not all measures of weekly consumptions. It also reduced weekly alcohol and craving related to placebo, and also led to a greater relative reduction in cigarettes per day.

The research also found that weekly injections of semaglutide, which is the active ingredient in weight loss drugs like Wegovy also helped reduce cravings in people with alcohol use disorder.

The lead author Christian Hendershot said that these findings will help in developing new approaches to treat alcoholism. "Two drugs currently approved to reduce alcohol consumption aren't widely used. The popularity of Ozempic and other GLP-1 receptor agonists increases the chances of broad adoption of these treatments for alcohol use disorder," said Hendershot in news release by the University of Southern California's Institute for Addiction Research, where he is the director.

The study is government-funded research and was funded by the National Institute on Alcohol Abuse and Alcoholism, part of the National Institutes of Health.

How Was The Study Conducted?

The study was small, and took in account for only 48 adults over two months, thus experts say that it is not yet clear how safe these drugs are for people who do not need to lose weight. Though the results do add up with the evidence form animal studies on drugs like Ozempic and Wegovy on how it helps manage cravings, not just for food, but also for tobacco and alcohol. Scientists are also studying these drugs on smokers, people with opioid addiction and cocaine users.

Co-author Dr Klara Klein of the University of North Carolina at Chapel Hill who treats people with obesity and diabetes said, "This is such promising data. And we need more of it. We frequently will hear that once people start these medications that their desire to drink is very reduced, if not completely abolished."

Why Does It Work So Well Against Alcoholism?

The GLP-1 receptor agonists work by mimicking hormones GLP-1 in the gut and brain that regulates appetite and feelings of fullness. This response is what helps one lose weight, and what helps one curb their craving for alcohol. These drugs that mimic the functioning of your brain, which is responsible to tell your body when to stop consuming, are the same hormones that tell your body about other kinds of consumptions, including alcohol. Therefore by consuming the weight loss drugs one can treat alcohol use disorder.

However, the researchers have pointed out on the limited data on the research and have suggested to continue using the three approved drugs by the National Institute on Alcohol Abuse and Alcoholism and Substance Abuse and Mental Health Services Administration, namely, Disulfiram, Naltrexone, and Acamprosate to treat alcohol use disorder until large studies confirm these findings.

The United States is witnessing a rise in cases of Powassan virus disease, a rare but potentially deadly illness transmitted through tick bites. Unlike many other tick-borne diseases, Powassan virus can be transmitted within 15 minutes of a tick attaching to the skin, making prevention and awareness especially important.

According to the US Centers for Disease Control and Prevention (CDC), tick exposure can occur throughout the year, although ticks are most active during the warmer months between April and September.

Emergency physician Dr. Rick Pescatore recently highlighted the growing threat in a TikTok video post, warning that many people remain unaware of the virus despite its severe health consequences.

"There's a new and deadly tick virus that's spreading across the United States, and you probably haven't heard about it," he said.

Pescatore emphasized the seriousness of the infection, noting that "about one in 10 people with severe disease die, while around half of survivors may experience permanent neurological damage". He also claimed that reported cases have increased steadily over the past decade.

Several state health departments have urged residents to take precautions after reporting cases of the rare disease.

In one recent case, a 66-year-old man from New Hampshire was hospitalized for several weeks after contracting the virus. After initially being admitted to Concord Hospital, he was later transferred to Massachusetts General Hospital for specialized care.

What Is Powassan Virus?

Also read: Taking Duloxetine? US FDA Warns of Cancer-Causing Impurity in Antidepressant

The Powassan virus is named after the town of Powassan in Ontario, Canada, where it was first identified in 1958. It belongs to the flavivirus family, which also includes viruses that cause Zika, dengue, and West Nile fever.

The virus is primarily spread by the black-legged tick (Ixodes scapularis), also known as the deer tick, which is also responsible for transmitting Lyme disease.

However, unlike Lyme disease—which generally requires a tick to remain attached for more than 24 hours before transmission—Powassan virus can be transmitted in as little as 15 minutes, according to the Massachusetts Department of Public Health.

Symptoms of Powassan Virus Infection

Read More: South Korea Achieves 62% Blood Pressure Control Rate: What Other Countries Can Learn

Symptoms typically develop between seven and 30 days after a tick bite and may include:

• Fever
• Headache
• Vomiting
• Weakness
• Confusion
• Loss of coordination
• Seizures
• Difficulty speaking

These complications can lead to long-term neurological damage. According to Yale Medicine, approximately 10 per cent of severe cases are fatal, while nearly 50 per cent of survivors experience lasting neurological problems.

No Vaccine or Treatment Available

One of the most concerning aspects of the Powassan virus is that there is currently no vaccine or antiviral treatment available.

Unlike Lyme disease, which can be treated with antibiotics, Powassan virus has no specific cure. Medical care focuses on managing symptoms and supporting patients with severe disease.

As a result, prevention remains the most effective defense against infection.

How to Prevent Tick Bites

The CDC and the National Institutes of Health (NIH) recommend the following measures to reduce the risk of tick bites:

• Wear long-sleeved shirts and long pants when outdoors
• Choose light-colored clothing to make ticks easier to spot
• Tuck pants into socks or seal gaps in clothing
• Use insect repellents containing DEET, picaridin, or permethrin
• Stay in the center of hiking trails and avoid brushing against vegetation
• Check your body, clothing, pets, and outdoor gear for ticks after spending time outside
• Shower and wash clothing in hot water soon after returning indoors

If you find a tick attached to your skin, remove it promptly using fine-tipped tweezers.

Amid the ongoing Ebola outbreak caused by the Bundibugyo virus in the Democratic Republic of the Congo (DRC), the World Health Organization (WHO) has released its first comprehensive guidelines for the clinical management of filovirus diseases, a group that includes all Ebola and Marburg virus infections.

Ebola and Marburg diseases are severe, often fatal illnesses that have caused repeated outbreaks across Africa. Since the discovery of the Marburg virus in 1967, there have been 72 documented outbreaks of Ebola and Marburg diseases.

There are currently no licensed vaccines and treatments for Marburg virus disease, as well as Bundibugyo and Sudan virus diseases. Thus, the WHO emphasized that early supportive care remains one of the most effective ways to improve survival.

"The current Bundibugyo virus outbreak is a stark reminder of the need for diligent, holistic and person-focused medical care to save lives and preserve human dignity. We encourage governments and authorities to integrate these new recommendations into preparedness and outbreak response to ensure high-quality care for everyone," said WHO Director-General Dr. Tedros Adhanom Ghebreyesus.

Also read: Ebola Bundibugyo Outbreak: UK Scientists Identify 23 Unique Mutations

What Do The New Guidelines Recommend?

The WHO has previously published disease-specific guidance on Ebola care and therapeutics. However, the newly released guidelines are the first to provide a comprehensive framework covering all filovirus diseases, including Ebola and Marburg.

Developed through consultations with global experts and based on the latest scientific evidence, the guidelines contain 16 evidence-based recommendations focused on improving supportive care and reducing mortality.

The recommendations are designed to help frontline healthcare workers:

• Identify clinical deterioration early
• Manage dehydration and shock effectively
• Improve patient monitoring
• Deliver critical supportive interventions safely
• Provide structured follow-up care for survivors

Key Recommendations include:

• Prioritizing Laboratory Testing
• Rapid Treatment of Dehydration
• Early Management of Shock
• Treatment should be guided by continuous monitoring of vital signs and indicators of tissue perfusion.
• Treat Secondary Bacterial Infections
• Provide Long-Term Follow-Up Care

The WHO also recommended structured after-care programs for survivors to support recovery, improve long-term well-being, and reduce the risk of infections linked to viral persistence after recovery.

Supportive Care Remains Critical

For Bundibugyo virus disease and other filovirus infections, WHO stressed that early recognition, rapid referral, and optimized supportive care remain the foundation of patient management.

Effective supportive care can reduce complications, improve survival, and provide the basis for evaluating potential antiviral treatments through future clinical research.

Ebola Outbreak Faced Major Contact-Tracing Gaps

Meanwhile, the Africa Centers for Disease Control and Prevention (Africa CDC) has raised concerns about significant weaknesses in contact-tracing efforts during the ongoing outbreak.

According to Africa CDC Director-General Dr. Jean Kaseya, more than 28,000 people who have been in contact with confirmed Ebola patients are currently not being monitored.

Responders should be tracking approximately 33,080 contacts, but only 4,112 are being actively followed, he said during a high-level meeting.

The agency warned that the outbreak is spreading at a pace that surveillance systems are struggling to keep up with.

Read More: Ebola Survivors May Face COVID-Like Memory Loss and Brain Issues For Over 7 Years: NIH Study

Ebola: More Than 800 Confirmed Cases

As per latest update till June 15, there are 827 confirmed Ebola cases linked to the outbreak in the Congo and 196 confirmed death.

Health officials estimate that each infected person may have come into contact with around 40 other individuals, creating a large pool of people at risk of infection.

Because Ebola can take up to 21 days for symptoms to appear, all identified contacts should ideally be monitored throughout the incubation period.

Africa CDC officials cautioned that without stronger surveillance and contact-tracing efforts, controlling the outbreak will become increasingly difficult, despite advances in clinical care and patient management.

Yet another study has highlighted the cardiovascular benefits of COVID-19 vaccination, particularly among older adults and people with underlying health conditions.

A new study involving nearly one million people, published in the journal JAMA Internal Medicine, found that COVID vaccination reduced the risk of major cardiovascular events associated with the virus—including heart attacks, strokes, and hospitalizations due to heart disease—by about 40 per cent.

The protective effect was most pronounced among adults aged 75 years and older, as well as individuals with pre-existing conditions such as cardiovascular disease, diabetes, and chronic lung disease.

The findings add to a growing body of evidence suggesting that COVID vaccines offer benefits beyond preventing severe infection.

Researchers also found that vaccination modestly reduced the risk of cardiovascular events, hospitalizations, and deaths from all causes, including those not directly linked to COVID.

"Extrapolating these estimates to a population of one million people, vaccination could plausibly be associated with averting approximately 2,370 major cardiovascular events and 1,580 deaths over an eight-month period," the study noted.

"It tells us that these vaccines have actually brought beneficial effects even in people who don't really know that they have contracted COVID-19," said Dr. Ziyad Al-Aly, physician-scientist and senior clinical epidemiologist at Washington University in St. Louis and co-author of the study, the Washington Post reported.

What Did the Study Find?

Also read: Trying to Quit Tobacco? Yoga Could Improve Your Chances, Suggests Study

Several previous studies have shown that COVID vaccination lowers the risk of heart attacks and strokes. However, researchers wanted to determine whether those benefits continued in the years after the onset of the pandemic, especially as both the virus and vaccine formulations evolved.

"Vaccine formulations have changed, and also the virus itself has changed over time," Al-Aly said. "But we found that the more recent vaccine formulations still protected against heart conditions."

The study analyzed nearly one million veterans receiving care through the US Department of Veterans Affairs health system between 2024 and 2025.

The participants were divided into two groups: individuals who received only the seasonal influenza vaccine and those who received both the flu vaccine and the updated COVID-19 vaccine during the same season. The analysis included multiple vaccine types, including mRNA vaccines and the Novavax vaccine.

Lower Risk of Heart Conditions

Read More: South Korea Achieves 62% Blood Pressure Control Rate: What Other Countries Can Learn

Participants were followed for approximately eight months. The results showed that people who received a COVID vaccine had a 37.7 per cent lower risk of developing COVID-associated cardiovascular complications.

Vaccinated individuals were also about 6 per cent less likely to experience severe cardiovascular events overall, including those not directly linked to COVID-19 infection.

In addition, vaccination was associated with:

• A 7 per cent reduction in all-cause hospitalizations
• A 7 per cent reduction in all-cause mortality
• Fewer severe cardiovascular events overall

While these percentages may appear modest, researchers emphasized that the public health impact is substantial.

According to Al-Aly, for every 10,000 people vaccinated, the findings translate into preventing approximately:

• 23 major cardiovascular events
• 30 hospitalizations
• 16 deaths

Benefits Outweigh Risk

COVID-19 vaccines have previously been linked to rare cases of myocarditis and pericarditis, conditions involving inflammation of the heart muscle and its surrounding lining.

However, experts note that these cases are uncommon and generally mild. Public health authorities continue to maintain that the benefits of vaccination far outweigh the potential risks.